Maximum tolerated dose evaluation of the AMPA modulator org 26576 in healthy volunteers and depressed patients: A summary and method analysis of bridging research in support of phase II dose selection

Drugs in R and D

Volumn 12, Issue 3, 2012, Pages 127-139

  Nations, Kari R ^a   Bursi, Roberta ^b   Dogterom, Peter ^b   Ereshefsky, Larry ^c,d   Gertsik, Lev ^c   Mant, Tim ^e   Schipper, Jacques ^b  

^a MERCK RESEARCH LABORATORIES   (United States)

^b NV ORGANON   (Netherlands)

^c CALIFORNIA CLINICAL TRIALS   (United States)

^d UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^e GUY S HOSPITAL   (United Kingdom)

Author keywords

AMPA receptor modulators; Major depressive disorder; Maximum tolerated dose; ORG 26576; Pharmacokinetics

Indexed keywords

AMPA RECEPTOR AGONIST; ORG 26576; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; HUMAN EXPERIMENT; MAJOR DEPRESSION; MALE; MAXIMUM TOLERATED DOSE; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; UNITED KINGDOM;

ADOLESCENT; ADULT; ALPHA-AMINO-3-HYDROXY-5-METHYL-4-ISOXAZOLEPROPIONIC ACID; DEPRESSION; DEPRESSIVE DISORDER, MAJOR; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; RECEPTORS, AMPA; YOUNG ADULT;

EID: 84865858577     PISSN: 11745886     EISSN: 11796901     Source Type: Journal    
DOI: 10.2165/11634360-000000000-00000     Document Type: Article

References (37)

1. Cutler NR, Sramek JJ, Murphy MF, et al. Critical pathways to success in CNS drug development. 1st ed. Oxford: Wiley-Blackwell, 2010
2. Sramek JJ, Cutler NR. Investigator perspective on MTD: practical application of an MTD definition - has it accelerated development? J Clin Pharmacol 2000; 40: 1184-7
3. Ereshefsky L, Jhee S, Gertsik L, et al. Strategies to accelerate drug development for CNS compounds: focus on schizophrenia [poster]. 15th Biennial Winter Workshop in Psychoses; 2009 Nov 15-18; Barcelona
4. Vanover K, Davis R, Ereshefsky L, et al. Safety, pharmacokinetics and early signals for efficacy of ITI-007, a novel investigational drug for the treatment of schizophrenia and related disorders [poster]. 13th International Congress on Schizophrenia Research; 2011 Apr 2-6; Colorado Springs (CO)
5. Cutler NJ, Sramek JJ. Guidelines for conducting bridging studies in Alzheimer's disease. Alzheimer Dis Assoc Disord 1998; 12 (2): 88-92
6. Cutler NR, Sramek JJ, Greenblatt DJ, et al. Defining the maximum tolerated dose: investigator, academic, industry, and regulatory perspectives. J Clin Pharmacol 1997; 37 (9): 767-83
7. Anand R, Geffen Y, Vasile D, et al. An open-label tolerability study of BL-1020 antipsychotic: a novel gamma aminobutyric acid ester of perhenazine. Clin Neuropharmacol 2010; 33 (6): 297-302
8. Fitzgerald PB. BL-1020: an oral antipsychotic agent that reduces dopamine activity and enhances GABAA activity, for the treatment of schizophrenia. Curr Opin Investig Drugs 2010; 11 (1): 92-100
9. Ereshefsky L, Gage A, Yu B, et al. Phase 1 study of RGH- 188 in schizophrenic patients [poster]. 161st Annual Meeting of the American Psychiatric Association; 2008 May 3-8; Washington, DC
10. Sramek JJ, Kirkesseli S, Paccaly-Moulin A, et al. A bridging study of fananserin in schizophrenic patients. Psychopharmacol Bull 1998; 34 (4): 811-8
11. Ereshefsky L, Jhee S, Phillips D, et al. Assessment of the maximum tolerated dose (MTD) of lurasidone in patients with schizophrenia [poster]. 48th Annual Meeting of the American College of Neuropsychopharmacology; 2010 Dec 6-10; Hollywood (FL)
12. Sramek JJ, Block GA, Reines SA, et al. A multiple-dose safety trial of epastigmine in Alzheimer's disease, with pharmacodynamic observations of red blood cell cholinesterase. Life Sci 1995; 56 (5): 319-26
13. Lefevre G, Sedek G, Jhee S, et al. Pharmacokinetics and pharmacodynamics of the novel daily rivastigmine transdermal patch comparedwith twice-daily capsules inAlzheimer's disease patients. Clin Pharmacol Ther 2008; 83 (1): 106-14
14. Gobburu JV, Tammara V, Lesko L, et al. Pharmacokineticpharmacodynamic modeling of rivastigmine, a cholinesterase inhibitor, in patients with Alzheimer's disease. J Clin Pharmacol 2001; 41 (10): 1082-90
15. Cutler NR, Jhee SS, Cyrus P, et al. Safety and tolerability of metrifonate: results of a maximum tolerated dose study. Life Sci 1996; 62 (16): 1433-41
16. Sramek JJ, Eldon MA, Posvar EL, et al. Initial safety, tolerability, pharmacodynamics, and pharmacokinetics of CI-1007 in patients with schizophrenia. Psychopharm Bull 1998; 34 (1): 93-8
17. Cutler NR, Murphy MF, Nash RJ, et al. Clinical safety, tolerance, and plasma levels of the oral anticholinesterase 1,2,3,4-tetrahydro-9-aminoacridin- 1-oL-maleate (HP 029) in Alzheimer's disease: preliminary findings. J Clin Pharmacol 1990; 30 (6): 556-61
18. Lynch G. Glutamate-based therapeutic approaches: ampakines. Curr Opin Pharmacol 2006; 6: 82-8
19. Arai AC, Kessler M. Pharmacology of ampakine modulators: from AMPA receptors to synapses and behaviour. Curr Drug Targets 2007; 8: 583-602
20. Deakin JFW, Slater P, Simpson MDC, et al. Frontal cortical and left temporal glutamatergic dysfunction in schizophrenia. J Neurochem 1989; 52: 1781-6
21. Kerwin R, Patel S, Meldrum B. Quantitative autoradiographic analysis of glutamate binding sites in the hippocampal formation in normal and schizophrenic brain post mortem. Neuroscience 1990; 39: 25-32
22. Mitani H, Shirayama Y, Yamada T, et al. Correlation between plasma levels of glutamate, alanine and serine with severity of depression. Prog Neuropsychopharmacol Biol Psychiatry 2006; 30: 1155-8
23. Frye MA, Tsai GE, Huggins T, et al. Low cerebrospinal fluid glutamate and glycine in refractory affective disorder. Biol Psychiatry 2006; 61: 162-6
24. Hashimoto K, Sawa A, Iyo M. Increased levels of glutamate in brains from patients with mood disorders. Biol Psychiatry 2007; 62: 1310-6
25. Lauterborn JC, Lynch G, Vanderklish P, et al. Positive modulation of AMPA receptors increases neurotrophin expression by hippocampal and cortical neurons. J Neurosci 2000; 20 (1): 8-21
26. Du J, Gray NA, Falke CA, et al. Modulation of synaptic plasticity by antimanic agents: the role of AMPA glutamate receptor subunit 1 synaptic expression. J Neurosci 2004; 24 (29): 6578-89
27. Bai F, Bergeron M, Nelson DL. Chronic AMPA receptor potentiator (LY451646) treatment increases cell proliferation in adult rat hippocampus. Neuropharmacology 2003; 44: 1013-21
28. Alt A, Nisenbaum ES, Bleakman D, et al. A role for AMPA receptors in mood disorders. Biochem Pharmacol 2006; 71: 1273-88
29. O'Neill MJ, Witkin JM. AMPA receptor potentiators: application for depression and Parkinson's disease. Curr Drug Targets 2007; 8: 603-20
30. Nations KR, Dogterom P, Bursi R, et al. Evaluation of Org 26576, an AMPA receptor positive allosteric modulator, in patients diagnosed with major depressive disorder: an exploratory, randomized, double-blind, placebo-controlled trial. J Psychopharmacol. In press
31. Rush AJ, Trivedi MH, Ibrahim HM, et al. The 16-item Quick Inventory of Depressive Symptomatology (QIDS) Clinician Rating (QIDS-C) and Self-Report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry 2003; 54: 573-83
32. Beck AT, Steer RA, Ranieri WF. Scale for suicide ideation: psychometric properties of a self-report version. J Clin Psychol 1988; 44: 499-505
33. Faassen F, Vromans H. Biowaivers for oral immediaterelease products: implications of linear pharmacokinetics. Clin Pharmacokinet 2004; 43 (15): 1117-26
34. Fleisher D, Li C, Zhou Y, et al. Drug, meal, and formulation interactions influencing drug absorption after oral administration: clinical implications. Clin Pharmacokinet 1999; 36: 233-54
35. Hashimoto K. The role of glutamate on the action of antidepressants. Prog Neuropsychopharmacol Biol Psychiatry 2011; 35: 1558-68
36. Beneyto M, Kristiansen LV, Oni-Orisan A, et al. Abnormal glutamate receptor expression in the medial temporal lobe in schizophrenia and mood disorders. Neuropsychopharmacology 2007; 32: 1888-902
37. Bursi R, Erdemli G, Campbell R, et al. Translational PKPD modelling of molecular target modulation for the AMPA receptor positive allosteric modulator Org 26576. Psychopharmacology (Berl) 2011; 218: 713-24